A third candidate – SAB05 – is also in preclinical development and is an antibody-glucocorticoid ... a standard anti-VEGF therapy – Roche’s Lucentis (ranibizumab) – compared to Lucentis ...
The KALAHARI study compared intravitreal injections of THR-149 to Regeneron and Bayer’s anti-VEGF antibody Eylea (aflibercept ... Roche/Novartis’ anti-VEGF Lucentis (ranibizumab).
After hours: 7:52:17 p.m. EST ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback